Verona Pharma plc VRNA NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • GB • USD

SharesGrow Score

33/100

0/7 Pass

SharesGrow Intrinsic Value

Income Statement Balance Sheet Cash Flow Statement

Annual Quarterly

Verona Pharma plc (VRNA) generated $30.56M in operating cash flow for quarter ending 2025-06-30. After capital expenditures of $0.00, free cash flow was $30.56M.

Free cash flow margin was 40.7% of revenue. Cash conversion ratio was 2.56x, indicating earnings are backed by cash.

Criteria supported by this page:

HEALTH (50/100, Partial) — cash generation is adequate but may not fully cover debt in stressed conditions
MOAT (53/100, Partial) — cash flow generation is present but not at levels indicating a wide moat
INCOME (10/100) — Cash conversion ratio was 2.56x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 33/100 with 0/7 criteria passed.

SharesGrow 7-Criteria Score

33/100

SG Score

View full scorecard →

VALUE

50/100

Price-to-Earnings & upside

→ Valuation

FUTURE

55/100

Analyst consensus

→ Forecast

✗

PAST

0/100

→ Income

HEALTH

50/100

Debt-to-Equity & liquidity

Proven by this page

MOAT

53/100

Proven by this page

✗

GROWTH

15/100

→ Income

✗

INCOME

10/100

→ Income

Verona Pharma plc Cash Flow History

Metric	TTM	Q2 FY2025	Q1 FY2025	Q4 FY2024	Q3 FY2024
Operating Cash Flow	$-72.48M	$30.56M	$-11.56M	$-28.84M	$-62.65M
Capital Expenditure	$-489.99K	$0.00	$0.00	$-535K	$45.01K
Free Cash Flow	$-73.03M	$30.56M	$-11.56M	$-29.37M	$-62.66M